Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Simcere Pharmaceutical Group Announces its Special Committee's Engagement of Legal Counsel



 Simcere Pharmaceutical Group Announces its Special Committee's Engagement of
                                Legal Counsel

PR Newswire

NANJING, China, March 12, 2013

NANJING, China, March 12, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group
("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China, today announced that its Special
Committee of the Board of Directors (the "Special Committee"), which was
formed to consider a proposal by Mr. Jinsheng Ren, New Good Management
Limited, Assure Ahead Investments Limited and its affiliates (the "Buyer
Group"), pursuant to which the Buyer Group proposes to acquire all of the
outstanding ordinary shares of the Company not currently owned by the Buyer
Group, and any potential alternative transactions involving the Company, has
retained Shearman & Sterling LLP as its legal counsel and is in the process of
engaging an independent financial advisor to assist it in its work. No
decisions have been made by the Special Committee with respect to the
Company's response to the proposed transaction. There can be no assurance that
any definitive offer will be made, that any agreement will be executed or that
this or any other transaction will be approved or consummated.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a
leading pharmaceutical company specializing in the development, manufacturing,
and marketing of branded and proprietary pharmaceuticals in China. Simcere
concentrates its research and development efforts on the treatment of diseases
with high incidence and/or mortality rates and for which there is a clear
demand for more effective pharmacotherapy such as cancer, strokes,
cardiovascular disease, infectious diseases and pain. For more information
about Simcere Pharmaceutical Group, please visit www.simcere.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements
constitute "forward-looking" statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as "anticipate," "believe,"
"estimate," "expect," "forecast," "intend," "may," "plan," "project,"
"predict," "should" and "will" and similar expressions. These statements are,
by their nature, subject to a number of risks and uncertainties that could
cause actual performance and results to differ materially from those discussed
in the forward-looking statements as a result of a number of factors. Further
information regarding these and other risks is included in Simcere's filings
with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does
not undertake any obligation to update any forward-looking statement, except
as required under applicable law.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:                  In the United States:

Jie Liu D'Elia               Cindy Zheng

Vice President               Brunswick Group LLC

Simcere Pharmaceutical Group Tel: 1-212-333-3810

Tel: 86-25-8556-6666*8857     
In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600

SOURCE Simcere Pharmaceutical Group

Website: http://www.simcere.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement